Literature DB >> 22373825

Differences in tissue degeneration between preoperative chemotherapy and preoperative chemoradiotherapy for colorectal cancer.

Yuji Nishizawa1, Satoshi Fujii, Norio Saito, Masaaki Ito, Kentaro Nakajima, Atsushi Ochiai, Masanori Sugito, Akihiro Kobayashi, Yusuke Nishizawa.   

Abstract

PURPOSE: Preoperative chemoradiotherapy (CRT) for rectal cancer is administered to improve local control, but can also induce severe anal dysfunction after surgery, while preoperative chemotherapy that significantly reduces the primary lesion in rectal cancer has recently been developed. The aim of the study was to examine differences in the effects of preoperative CRT and chemotherapy on tissue degeneration of patients with colorectal cancer.
METHODS: The subjects were 91 patients, including 68 with rectal cancer who underwent internal sphincteric resection with (n = 47, CRT group) or without (n = 21, control group) preoperative CRT, and 23 with colorectal cancer who received preoperative FOLFOX treatment. Peripheral nerve degeneration was evaluated histopathologically using H&E-stained sections, based on karyopyknosis, disparity of the nucleus, denucleation, vacuolar or acidophilic degeneration of the cytoplasm, and adventitial neuronal changes.
RESULTS: The incidence of neural degeneration was significantly higher in the CRT group than in the control group and FOLFOX group. There were no differences in any items of neural degeneration between the FOLFOX and control groups.
CONCLUSION: CRT induced marked neural degeneration around the rectal tumor. FOLFOX treatment produced mild neural degeneration similar to that in the control group.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22373825     DOI: 10.1007/s00384-012-1434-6

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  32 in total

1.  Prospective, randomized trial comparing intraoperative colonic irrigation with manual decompression only for obstructed left-sided colorectal cancer.

Authors:  J F Lim; C-L Tang; F Seow-Choen; S M Heah
Journal:  Dis Colon Rectum       Date:  2005-02       Impact factor: 4.585

2.  The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function.

Authors:  C F Kollmorgen; A P Meagher; B G Wolff; J H Pemberton; J A Martenson; D M Illstrup
Journal:  Ann Surg       Date:  1994-11       Impact factor: 12.969

3.  Treatment of rectal cancer by low anterior resection with coloanal anastomosis.

Authors:  P B Paty; W E Enker; A M Cohen; G Y Lauwers
Journal:  Ann Surg       Date:  1994-04       Impact factor: 12.969

4.  Oncologic outcome of intersphincteric resection for very low rectal cancer.

Authors:  Norio Saito; Masanori Sugito; Masaaki Ito; Akihiro Kobayashi; Yusuke Nishizawa; Yasuo Yoneyama; Yuji Nishizawa; Nozomi Minagawa
Journal:  World J Surg       Date:  2009-08       Impact factor: 3.352

5.  Ultralow anterior resection with intersphincteric dissection--what is the limit of safe sphincter preservation?

Authors:  E Tiret; B Poupardin; D McNamara; N Dehni; R Parc
Journal:  Colorectal Dis       Date:  2003-09       Impact factor: 3.788

6.  Intersphincteric resection for low rectal tumours.

Authors:  R Schiessel; J Karner-Hanusch; F Herbst; B Teleky; M Wunderlich
Journal:  Br J Surg       Date:  1994-09       Impact factor: 6.939

7.  Early experience with postoperative adjuvant chemoradiation for rectal carcinoma: focus on morbidity.

Authors:  F C Chen; J R Mackay; R J Woods; B T Collopy; R J Fink; M J Guiney
Journal:  Aust N Z J Surg       Date:  1995-10

8.  Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.

Authors:  Rainer Porschen; Hendrik-Tobias Arkenau; Stephan Kubicka; Richard Greil; Thomas Seufferlein; Werner Freier; Albrecht Kretzschmar; Ullrich Graeven; Axel Grothey; Axel Hinke; Wolff Schmiegel; Hans-Joachim Schmoll
Journal:  J Clin Oncol       Date:  2007-06-04       Impact factor: 44.544

9.  Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.

Authors:  Eduardo Díaz-Rubio; Jose Tabernero; Auxiliadora Gómez-España; Bartomeu Massutí; Javier Sastre; Manuel Chaves; Alberto Abad; Alfredo Carrato; Bernardo Queralt; Juan José Reina; Joan Maurel; Encarnación González-Flores; Jorge Aparicio; Fernando Rivera; Ferrán Losa; Enrique Aranda
Journal:  J Clin Oncol       Date:  2007-06-04       Impact factor: 44.544

10.  Long-term results of intersphincteric resection for low rectal cancer.

Authors:  Reza Chamlou; Yann Parc; Tabassome Simon; Malika Bennis; Nidal Dehni; Rolland Parc; Emmanuel Tiret
Journal:  Ann Surg       Date:  2007-12       Impact factor: 12.969

View more
  4 in total

1.  Influence of neoadjuvant chemoradiotherapy on the anal sphincter: ultrastructural damage may be critical.

Authors:  Xiaoming Zhu; Zheng Lou; Haifeng Gong; Ronggui Meng; Liqiang Hao; Wei Zhang
Journal:  Int J Colorectal Dis       Date:  2016-06-08       Impact factor: 2.571

2.  Association between pathologic features of peripheral nerves and postoperative anal function after neoadjuvant therapy for low rectal cancer.

Authors:  Keinchi Koushi; Yuji Nishizawa; Motohiro Kojima; Satoshi Fujii; Norio Saito; Ryuichi Hayashi; Atsushi Ochiai; Masaaki Ito
Journal:  Int J Colorectal Dis       Date:  2016-09-21       Impact factor: 2.571

3.  Laparoscopic lateral pelvic lymph node dissection for lower rectal cancer treated with preoperative chemoradiotherapy.

Authors:  Takeru Matsuda; Hiroshi Hasegawa; Kimihiro Yamashita; Tomoko Tanaka; Masashi Yamamoto; Shingo Kanaji; Taro Oshikiri; Tetsu Nakamura; Yasuo Sumi; Satoshi Suzuki; Yoshihiro Kakeji
Journal:  Surg Endosc       Date:  2019-10-18       Impact factor: 4.584

4.  Area of residual tumor is a robust prognostic marker for patients with rectal cancer undergoing preoperative therapy.

Authors:  Naoki Sakuyama; Motohiro Kojima; Shingo Kawano; Yoko Matsuda; Mari Mino-Kenudson; Atsushi Ochiai; Masaaki Ito
Journal:  Cancer Sci       Date:  2018-03       Impact factor: 6.716

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.